Rocket Pharmaceuticals Announces Second Quarter 2025 Results, Reshapes Strategic Focus Around Cardiovascular Gene Therapy Platform, and Advances Late-Stage Pipeline Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company developing a sustainable portfolio of genetic therapies for rare disorders…
Spine BioPharma Releases Phase 3 Data for SB-01 in Chronic Low Back Pain: Trial Misses Primary Endpoint Amid Strong Safety and Subgroup Efficacy Signals Spine BioPharma, Inc., a clinical-stage biopharmaceutical company advancing non-surgical treatments for spine-related pain, has announced topline…
Merck Completes €665 Million Divestment of Surface Solutions Business to GNMI, Marking Strategic Realignment Toward Innovation-Focused Growth In a decisive move underscoring its strategic emphasis on core technological and scientific capabilities, Merck, the global science and technology powerhouse headquartered in…
AeroRx Therapeutics Reports Positive Phase 2a Results for Inhaled AERO-007, the First Nebulized LABA/LAMA Combination Therapy in Development for COPD AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in proprietary nebulized combination therapies for chronic respiratory diseases, has announced encouraging…
KKR Acquires Majority Stake in HealthCare Royalty Partners, Expanding Life Sciences Strategy and Biopharma Royalty Capabilities KKR & Co. Inc., one of the world’s foremost investment firms, has announced a transformative acquisition: the majority ownership of HealthCare Royalty Partners (HCRx),…
Grifols Reports Strong First Half 2025 Results with Robust Revenue Growth, Rising Profitability, and Strategic Progress Across Business Units Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and a world leader in plasma-derived medicines, has announced a strong set of…
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Early-Stage Lung Cancer, Expanding Its Role in Perioperative NSCLC Treatment BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company committed to transforming cancer care through next-generation immunotherapy,…
MaaT Pharma Secures €37.5 Million EIB Loan to Propel Hemato-Oncology Pipeline and Microbiome Therapy Leadership MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company pioneering Microbiome Ecosystem Therapies™ (MET) to improve survival outcomes in cancer patients through immune modulation, announced a…
Alloy Therapeutics and KSAC Forge Strategic Alliance to Propel Global Growth of Japanese Life Science Startups Alloy Therapeutics Co. Ltd. (“Alloy Japan”) has entered into a strategic Memorandum of Understanding (MOU) with the Kansai Startup Academia Coalition (KSAC), an initiative…
MEI Pharma Makes Historic Move with $100 Million Private Placement to Launch Litecoin-Based Treasury Strategy, Appoints Charlie Lee to Board In a bold and unprecedented move that bridges the worlds of biotechnology and cryptocurrency, MEI Pharma, Inc. (Nasdaq: MEIP) has…
Bristol Myers Squibb Reports Topline Results from Phase 3 INDEPENDENCE Trial of Reblozyl in Myelofibrosis-Associated Anemia Bristol Myers Squibb (NYSE: BMY), a global leader in hematology and oncology innovation, has announced the topline results from its Phase 3 INDEPENDENCE trial…
PCI Pharma Services Embarks on Next Growth Phase with Strategic Investment from Bain Capital, Kohlberg, and Mubadala PCI Pharma Services (PCI), a globally recognized contract development and manufacturing organization (CDMO) specializing in cutting-edge biopharmaceuticals, has announced a major strategic investment…